Literature DB >> 32595082

Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs - A study based on blood sample analyses from 24,239 patients.

Robert L Smith1, Marit Tveito2, Lennart Kyllesø3, Marin M Jukic4, Magnus Ingelman-Sundberg5, Ole A Andreassen6, Espen Molden7.   

Abstract

Nonadherence to oral antipsychotic drugs is a major issue in clinical psychiatry giving rise to treatment failure. Further, polypharmacy is common in the treatment of psychotic disorders due to insufficient treatment effect during monotherapy. As a potential circuit problem, we hypothesized that antipsychotic polypharmacy is associated with increased risk of nonadherence. To investigate this, in terms of 'complete' nonadherence, the rates of undetectable serum drug concentrations during prescribing of doses used in psychotic disorders were compared during antipsychotic 'monotherapy' vs 'polypharmacy' treatment using therapeutic drug monitoring (TDM) data of 24,239 patients. A complete nonadherence patient was objectively defined as the detection of at least one event of undetectable serum concentration of a prescribed antipsychotic drug. The rate of complete nonadherence patients was compared between antipsychotic monotherapy and polypharmacy by multivariate logistic regression analyses. The overall rate of complete nonadherence in the population was 6.8% (n = 1,644; 95%CI: 6.5-7.1). Compared to monotherapy patients, the rate of nonadherence increased significantly with the number of co-prescribed antipsychotic drugs. After adjusting for sex (p = 0.091) and age (p < 0.001) as covariates, the rates of nonadherence vs monotherapy were 1.69-fold (95% CI: 1.48-1.92; p < 0.001) for two, 2.60-fold (95% CI: 1.88-3.59; p < 0.001) for three, and 3.54-fold (95% CI: 1.46-8.58; p = 0.005) for four or more co-prescribed antipsychotics, respectively. The present naturalistic study shows that antipsychotic polypharmacy significantly increases the rate of complete nonadherence, which is positively correlated with increasing number of concurrently used antipsychotic drugs. Thus, the intended clinical benefit of combining oral antipsychotic drugs may probably be reduced by increased nonadherence.
Copyright © 2020 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Antipsychotic drugs; Nonadherence; Polypharmacy; Therapeutic drug monitoring

Year:  2020        PMID: 32595082     DOI: 10.1016/j.euroneuro.2020.06.007

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  3 in total

1.  Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients.

Authors:  Lennart Kyllesø; Robert Løvsletten Smith; Øystein Karlstad; Ole A Andreassen; Espen Molden
Journal:  CNS Drugs       Date:  2021-08-20       Impact factor: 5.749

2.  Antipsychotic Polypharmacy and High-Dose Antipsychotic Regimens in the Residential Italian Forensic Psychiatric Population (REMS).

Authors:  Gabriele Mandarelli; Felice Carabellese; Guido Di Sciascio; Roberto Catanesi
Journal:  Front Psychol       Date:  2022-02-10

3.  Impact of age and gender on paliperidone exposure in patients after administration of long-acting injectable formulations-an observational study using blood samples from 1223 patients.

Authors:  Marit Tveito; Gudrun Høiseth; Tore Haslemo; Espen Molden; Robert Løvsletten Smith
Journal:  Eur J Clin Pharmacol       Date:  2021-02-22       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.